ClinicalTrials.gg
CompletedNCT03873246Updated Jun 8, 2022Results posted

Clinical Trial to Evaluate the Chronic Efficacy of OC-01 Nasal Spray on Signs of Dry Eye Disease (The MYSTIC Study)

A Phase 2 interventional study of OC-01 0.1% 0.6 mg/ml and OC-01 (varenicline) nasal spray: 0.2 % (1.2 mg/ml) in Dry Eye Disease, sponsored by Oyster Point Pharma, Inc.. Completed at 1 site in Mexico. Open to participants aged 22 Years and older. Per ClinicalTrials.gov, last updated 2022-06-08.

Sponsored by Oyster Point Pharma, Inc. (part of Viatris Inc.) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
123
Allocation
Randomized
Ages
22 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 13 studies testing varenicline in Dry Eye Syndromes — 2 open to participants now, 2 under way, none of them phase 3. Varenicline · Dry Eye Syndromes.

Enrollment
4th of 13
123 · median 60
Started
2019
with 1 other
Phase 2
3 of 13
none open now
Registered
3rd of 13
by date
Lead sponsor
4 of 13
Oyster Point Pharma, Inc.

Among the 13 studies testing varenicline in Dry Eye Syndromes, this one is the 4th largest by enrollment, is one of 2 that started in 2019, is one of 3 in phase 2, and was the 3rd registered.

Dry Eye Syndromes

1,369 studies on the registry are indexed under Dry Eye Syndromes; 208 are open to participants now.

Browse Dry Eye Syndromes studies →

Open to participants now

2 of the 13 studies testing varenicline in Dry Eye Syndromes are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

About varenicline

Varenicline: first FDA approval 2006 (CHANTIX), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 116 Dry Eye Syndromes studies recruiting now, 73 (63%) set no upper age limit and 24 (21%) stop at 75 or younger; 7 take children under 18; 29 take healthy volunteers.

This study: 22 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing varenicline in Dry Eye Syndromes, or all of them as a file.
02

Study summary

The objective of this study is to evaluate the chronic safety and effectiveness of OC-01 Nasal Spray as compared to placebo on signs of dry eye disease (DED).

Read the detailed description

Study OPP-004 was a Phase 2, single-center, randomized, masked (including subjects, Investigators, and study site personnel), placebo-controlled study designed to evaluate the safety and efficacy of OC-01 (varenicline) nasal spray in adult subjects with DED. The study planned to randomize approximately 120 subjects at least 22 years of age with a physicians' diagnosis of Dry Eye Disease and meeting all other study eligibility criteria to receive an application of OC-01 or placebo BID for 12 weeks. Subjects who terminated early during the application period were asked to complete safety assessments (if the subjects agree) prior to study exit. Subjects who were terminated early from the study were not replaced.

03

Conditions studied

  • Dry Eye Disease

Browse trials for

04

Who can participate

Ages eligible
22 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have used and/or desired to us an artificial tear substitute for dry eye symptoms within 6 months prior to Visit 1

Exclusion criteria

Exclusion Criteria:

  • Have had any intraocular surgery (such as cataract surgery), extraocular surgery (such as blepharoplasty) in either eye within three months or refractive surgery (e.g. laser-assisted in-situ keratomileusis, laser epithelial keratomileusis, photorefractive keratectomy or corneal implant) within twelve months of Visit 1
  • Have a history or presence of an ocular disorder or condition in either eye that would, in the opinion of the Investigator, likely interfere with the interpretation of the study results or participant safety such as significant corneal or conjunctival scarring; pterygium or nodular pinguecula; current ocular infection, conjunctivitis, or inflammation not associated with dry eye; anterior (epithelial) basement membrane corneal dystrophy or other corneal dystrophy or degeneration; ocular herpetic infection; evidence of keratoconus; etc. Blepharitis not requiring treatment and mild meibomian gland disease that are typically associated with DED are allowed.
  • Have a systemic condition or disease not stabilized or judged by the Investigator to be incompatible with participation in the study or with the lengthier assessments required by the study (e.g., current systemic infection, uncontrolled disease, uncontrolled immunodeficiency disease, history of myocardial infarction or heart disease, etc.)
  • Have a known to any of the procedural agents or study drug components
  • Have any condition or history that, in the opinion of the investigator, may interfere with study compliance, outcome measures, safety parameters, and/or the general medical condition of the subject
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
123 participants (actual)

Study arms

  • Active comparator
    OC-01 0.1%, 0.6 mg/ml

    OC-01 (varenicline) nasal spray, 0.6 mg/mL

    Drug: OC-01 0.1% 0.6 mg/ml

  • Active comparator
    OC-01 0.2%, 1.2 mg/ml

    OC-01 (varenicline) nasal spray, 1.2 mg/mL

    Drug: OC-01 (varenicline) nasal spray: 0.2 % (1.2 mg/ml)

  • Placebo comparator
    Placebo

    vehicle control

    Other: placebo comparator

Interventions

  • DrugOC-01 0.1% 0.6 mg/ml

    Drug page: Varenicline

    OC-01 (varenicline) nasal spray: 0.1 % (0.6 mg/ml)

    Also known as: varenicline

  • DrugOC-01 (varenicline) nasal spray: 0.2 % (1.2 mg/ml)

    Drug page: Varenicline

    OC-01 (varenicline) nasal spray: 0.2 % (1.2 mg/ml)

    Also known as: varenicline

  • Otherplacebo comparator

    vehicle control

06

What researchers measure

Primary outcomes

  1. Mean Change in Schirmer's Test Score From Baseline to 84 Days

    The Schirmer's test measures the amount of tears produced by numbing the eye and placing a paper strip in the eye for 5 minutes and distance of wetting was recorded following treatment with OC-01 or placebo. Schirmer's test scores range from 0-35 mm where a higher score is indicative of a better outcome.

    Time frame: Visit 1 (baseline) and Visit 6 (84 days)

Other outcomes

  1. Percent of Subjects Who Achieve ≥10 mm Improvement in Schirmer's Test Score From Baseline at Visit 6 (Day 84)

    The Schirmer's test measures the amount of tears produced by numbing the eye and placing a paper strip in the eye for 5 minutes and distance of wetting was recorded following treatment with OC-01 or placebo. Schirmer's test scores range from 0-35 mm where a higher score is indicative of a better outcome.

    Time frame: Visit 1 (baseline) and Visit 6 (84 days)

  2. Percent of Subjects Who Achieve ≥10 mm Improvement in Schirmer's Test Score From Baseline at Visit 4 (Day 28)

    The Schirmer's test measures the amount of tears produced by placing a paper strip in the eye for 5 minutes and the distance of wetting was recorded following treatment with OC-01 or placebo. Schirmer's test scores range from 0-35 mm where a higher score is indicative of a better outcome.

    Time frame: Visit 1 (baseline) and Visit 4 (28 Days)

  3. Mean Change in Schirmer's Test Score From Baseline to 84 Days (Visit 6) - Fellow Eye

    The Schirmer's test measures the amount of tears produced by numbing the eye and placing a paper strip in the eye for 5 minutes and distance of wetting was recorded following treatment with OC-01 or placebo. Schirmer's test scores range from 0-35 mm where a higher score is indicative of a better outcome.

    Time frame: Visit 1 (baseline) to Visit 6 (84 Days)

  4. Mean Change in Schirmer's Test Score From Baseline to 28 Days (Visit 4) - Study Eye

    The Schirmer's test measures the amount of tears produced by numbing the eye and placing a paper strip in the eye for 5 minutes and distance of wetting was recorded following treatment of OC-01 or placebo. Schirmer's test scores range from 0-35 mm where a higher score is indicative of a better outcome.

    Time frame: Visit 1 (baseline) to Visit 4 (28 days)]

  5. Mean Change in Schirmer's Test Score From Baseline to 28 Days (Visit 4) - Fellow Eye

    The Schirmer's test measures the amount of tears produced by numbing the eye and placing a paper strip in the eye for 5 minutes and distance of wetting was recorded following treatment with OC-01 or placebo. Schirmer's test scores range from 0-35 mm where a higher score is indicative of a better outcome.

    Time frame: Visit 1 (baseline) to Visit 4 (28 Days)

  6. Mean Change in Total Corneal Fluorescein Staining

    A standardized grading system of 0-3 is used for each of the five areas of the cornea (inferior, superior, nasal, temporal, central). Grade 0 will be specified when no staining is present. The total score ranges from 0-15. Lower scores indicate improvement.

    Time frame: Visit 1 (baseline) and Visit 5 (56 days)

07

Results

Posted Jun 8, 2022

Participant flow

Participant flow — Overall Study
MilestoneOC-01 0.1%, 0.6 mg/mlOC-01 0.2%, 1.2 mg/mlPlacebo
Started414141
Completed362932
Not completed5129
Withdrew: Adverse event133
Withdrew: Lost to follow-up445
Withdrew: Protocol violation010
Withdrew: Withdrawal by subject041

Outcome measures

PrimaryMean Change in Schirmer's Test Score From Baseline to 84 Days

The Schirmer's test measures the amount of tears produced by numbing the eye and placing a paper strip in the eye for 5 minutes and distance of wetting was recorded following treatment with OC-01 or placebo. Schirmer's test scores range from 0-35 mm where a higher score is indicative of a better outcome.

Time frame:
Visit 1 (baseline) and Visit 6 (84 days)
Reported as:
Least squares mean · mm
Mean Change in Schirmer's Test Score From Baseline to 84 Days
mmOC-01 0.1%, 0.6 mg/mlOC-01 0.2%. 1.2 mg/mlPlacebo
Mean Change in Schirmer's Test Score From Baseline to 84 Days10.8 ± 1.2911.0 ± 1.296.0 ± 1.29
Other pre-specifiedPercent of Subjects Who Achieve ≥10 mm Improvement in Schirmer's Test Score From Baseline at Visit 6 (Day 84)

The Schirmer's test measures the amount of tears produced by numbing the eye and placing a paper strip in the eye for 5 minutes and distance of wetting was recorded following treatment with OC-01 or placebo. Schirmer's test scores range from 0-35 mm where a higher score is indicative of a better outcome.

Time frame:
Visit 1 (baseline) and Visit 6 (84 days)
Reported as:
Count of participants · Participants
Percent of Subjects Who Achieve ≥10 mm Improvement in Schirmer's Test Score From Baseline at Visit 6 (Day 84)
ParticipantsOC-01 0.1%, 0.6 mg/mlOC-01 0.2%, 1.2 mg/mlPlacebo
Percent of Subjects Who Achieve ≥10 mm Improvement in Schirmer's Test Score From Baseline at Visit 6 (Day 84)152010
Other pre-specifiedPercent of Subjects Who Achieve ≥10 mm Improvement in Schirmer's Test Score From Baseline at Visit 4 (Day 28)

The Schirmer's test measures the amount of tears produced by placing a paper strip in the eye for 5 minutes and the distance of wetting was recorded following treatment with OC-01 or placebo. Schirmer's test scores range from 0-35 mm where a higher score is indicative of a better outcome.

Time frame:
Visit 1 (baseline) and Visit 4 (28 Days)
Reported as:
Count of participants · Participants
Percent of Subjects Who Achieve ≥10 mm Improvement in Schirmer's Test Score From Baseline at Visit 4 (Day 28)
ParticipantsOC-01 0.1%, 0.6 mg/mlOC-01 0.2%. 1.2 mg/mlPlacebo
Percent of Subjects Who Achieve ≥10 mm Improvement in Schirmer's Test Score From Baseline at Visit 4 (Day 28)181712
Other pre-specifiedMean Change in Schirmer's Test Score From Baseline to 84 Days (Visit 6) - Fellow Eye

The Schirmer's test measures the amount of tears produced by numbing the eye and placing a paper strip in the eye for 5 minutes and distance of wetting was recorded following treatment with OC-01 or placebo. Schirmer's test scores range from 0-35 mm where a higher score is indicative of a better outcome.

Time frame:
Visit 1 (baseline) to Visit 6 (84 Days)
Reported as:
Least squares mean · mm
Mean Change in Schirmer's Test Score From Baseline to 84 Days (Visit 6) - Fellow Eye
mmOC-01 0.1%, 0.6 mg/mlOC-01 0.2%. 1.2 mg/mlPlacebo
Mean Change in Schirmer's Test Score From Baseline to 84 Days (Visit 6) - Fellow Eye7.9 ± 1.198.7 ± 1.184.8 ± 1.18
Other pre-specifiedMean Change in Schirmer's Test Score From Baseline to 28 Days (Visit 4) - Study Eye

The Schirmer's test measures the amount of tears produced by numbing the eye and placing a paper strip in the eye for 5 minutes and distance of wetting was recorded following treatment of OC-01 or placebo. Schirmer's test scores range from 0-35 mm where a higher score is indicative of a better outcome.

Time frame:
Visit 1 (baseline) to Visit 4 (28 days)]
Reported as:
Least squares mean · mm
Mean Change in Schirmer's Test Score From Baseline to 28 Days (Visit 4) - Study Eye
mmOC-01 0.1%, 0.6 mg/mlOC-01 0.2%. 1.2 mg/mlPlacebo
Mean Change in Schirmer's Test Score From Baseline to 28 Days (Visit 4) - Study Eye10.2 ± 1.4211.4 ± 1.426.9 ± 1.42
Other pre-specifiedMean Change in Schirmer's Test Score From Baseline to 28 Days (Visit 4) - Fellow Eye

The Schirmer's test measures the amount of tears produced by numbing the eye and placing a paper strip in the eye for 5 minutes and distance of wetting was recorded following treatment with OC-01 or placebo. Schirmer's test scores range from 0-35 mm where a higher score is indicative of a better outcome.

Time frame:
Visit 1 (baseline) to Visit 4 (28 Days)
Reported as:
Least squares mean · mm
Mean Change in Schirmer's Test Score From Baseline to 28 Days (Visit 4) - Fellow Eye
mmOC-01 0.1%, 0.6 mg/mlOC-01 0.2%. 1.2 mg/mlPlacebo
Mean Change in Schirmer's Test Score From Baseline to 28 Days (Visit 4) - Fellow Eye5.4 ± 1.369.2 ± 1.356.7 ± 1.35
Other pre-specifiedMean Change in Total Corneal Fluorescein Staining

A standardized grading system of 0-3 is used for each of the five areas of the cornea (inferior, superior, nasal, temporal, central). Grade 0 will be specified when no staining is present. The total score ranges from 0-15. Lower scores indicate improvement.

Time frame:
Visit 1 (baseline) and Visit 5 (56 days)
Reported as:
Least squares mean · units on a scale
Mean Change in Total Corneal Fluorescein Staining
units on a scaleOC-01 0.1%, 0.6 mg/mlOC-01 0.2%, 1.2 mg/mlPlacebo
Mean Change in Total Corneal Fluorescein Staining-3.3 ± 0.56-3.7 ± 0.6-3.2 ± 0.59

Adverse events

Collected over Adverse Events were collected from the first dose of study drug administration until the final study visit at Visit 6 (84 days).. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
OC-01 0.1%, 0.6 mg/ml0/41 (0%)0/41 (0%)4/41 (9.8%)
OC-01 0.2%, 1.2 mg/ml0/41 (0%)0/41 (0%)5/41 (12.2%)
Placebo0/41 (0%)0/41 (0%)4/41 (9.8%)
Most frequent other events
Showing 10 of 11
Most frequent other events
EventOC-01 0.1%, 0.6 mg/mlOC-01 0.2%, 1.2 mg/mlPlacebo
Ocular TEAEsEye disorders4/415/414/41
Visual acuity reducedEye disorders4/413/413/41
SneezingRespiratory, thoracic and mediastinal disorders2/413/412/41
EpistaxisRespiratory, thoracic and mediastinal disorders0/410/412/41
Throat irritationRespiratory, thoracic and mediastinal disorders2/410/410/41
HeadacheNervous system disorders2/412/410/41
NauseaGastrointestinal disorders0/411/412/41
Conjunctival hyperaemiaEye disorders0/410/411/41
Eye irritationEye disorders0/411/410/41
Eyelid oedemaEye disorders0/410/411/41

Baseline characteristics

Subjects in the ITT population

Age, Continuous
Age, Continuous(years)OC-01 0.1%, 0.6 mg/mlOC-01 0.2%, 1.2 mg/mlPlaceboTotal
Mean51.4 ± 13.1854.2 ± 11.7755.8 ± 26.7753.8 ± 12.75
Sex: Female, Male
Sex: Female, Male(Participants)OC-01 0.1%, 0.6 mg/mlOC-01 0.2%, 1.2 mg/mlPlaceboTotal
Female323533100
Male96823
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)OC-01 0.1%, 0.6 mg/mlOC-01 0.2%, 1.2 mg/mlPlaceboTotal
Race, Other414141123
Hispanic or Latino414141123
Baseline Schirmer's Test Score
Baseline Schirmer's Test Score(mm)OC-01 0.1%, 0.6 mg/mlOC-01 0.2%, 1.2 mg/mlPlaceboTotal
Mean5.5 ± 2.465.4 ± 2.475.3 ± 2.045.4 ± 2.33
08

Study locations

1 site
  • Mexico City
    Mexico City, Mexico
09

References and documents

Publications

  • Quiroz-Mercado H, Hernandez-Quintela E, Chiu KH, Henry E, Nau JA. A phase II randomized trial to evaluate the long-term (12-week) efficacy and safety of OC-01 (varenicline solution) nasal spray for dry eye disease: The MYSTIC study. Ocul Surf. 2022 Apr;24:15-21. doi: 10.1016/j.jtos.2021.12.007. Epub 2021 Dec 15. PubMed 34920097 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2019 to primary completion in Jan 2020, 10 months.

Results were first posted in Jun 2022, 2 years 5 months after primary completion.

Of 75 industry-sponsored phase 2 interventional studies under Dry Eye Syndromes, half reached primary completion within 7 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 11. This study's 10 months is above that.

Counting every sponsor, half of 91 studies reached it within 7 months; a quarter within 5 and three quarters within 12.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 11, 2019
First posted
Mar 13, 2019
StartActual
Feb 18, 2019
Primary completionActual
Jan 7, 2020
CompletionActual
Jan 7, 2020
Results first posted
Jun 8, 2022
Last update
Jun 8, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 8, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03873246
Responsible party
Sponsor
First posted
Mar 13, 2019
Start date
Feb 18, 2019
Primary completion
Jan 7, 2020
Completion
Jan 7, 2020
Results posted
Jun 8, 2022
Last update
Jun 8, 2022

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Varenicline

Start the discussion